76,916 Shares in Astrana Health, Inc. (NASDAQ:ASTH) Purchased by Barclays PLC

Barclays PLC acquired a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 76,916 shares of the company's stock, valued at approximately $4,457,000. Barclays PLC owned 0.14% of Astrana Health as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ASTH. State Street Corp acquired a new stake in Astrana Health in the third quarter worth $91,966,000. FMR LLC acquired a new stake in shares of Astrana Health in the 3rd quarter worth about $48,413,000. SteelPeak Wealth LLC bought a new stake in Astrana Health in the 3rd quarter valued at about $39,398,000. Loomis Sayles & Co. L P acquired a new position in Astrana Health during the 3rd quarter valued at about $30,251,000. Finally, NorthCrest Asset Manangement LLC bought a new position in Astrana Health in the 3rd quarter worth about $26,704,000. Institutional investors own 52.77% of the company's stock.

Astrana Health Price Performance

NASDAQ ASTH traded down $1.39 on Friday, reaching $33.70. The company's stock had a trading volume of 1,050,296 shares, compared to its average volume of 217,520. Astrana Health, Inc. has a twelve month low of $33.44 and a twelve month high of $63.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The firm's 50 day moving average is $47.22 and its two-hundred day moving average is $47.92. The stock has a market cap of $1.90 billion, a PE ratio of 25.92, a PEG ratio of 1.80 and a beta of 1.13.

Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting analysts' consensus estimates of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $478.71 million during the quarter, compared to analysts' expectations of $462.01 million. During the same period last year, the firm posted $0.47 earnings per share. As a group, sell-side analysts predict that Astrana Health, Inc. will post 1.16 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ASTH shares. Macquarie upgraded Astrana Health to a "hold" rating in a research report on Monday, December 16th. TD Cowen started coverage on Astrana Health in a research note on Monday, October 14th. They issued a "buy" rating and a $66.00 price target for the company. BTIG Research lifted their price objective on shares of Astrana Health from $60.00 to $70.00 and gave the company a "buy" rating in a research note on Thursday, October 3rd. Robert W. Baird upped their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Finally, KeyCorp started coverage on shares of Astrana Health in a research note on Friday, October 11th. They set a "sector weight" rating on the stock. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $65.17.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.